How BLD Helps
Metallic Radionuclides-chelating Agents Inspired by Pluvicto
25 March 2022
1,4,7-Triazacyclononane
2,2',2''-(1,4,7-Triazonane-1,4,7-triyl)triacetic acid
Di-tert-butyl 2,2'-(1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate
Tri-tert-butyl 2,2',2''-(10-(2-(but-3-yn-1-ylamino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
Tri-tert-Butyl 1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate
2,2',2'',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetamide
Sodium 2,2',2''-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
Novartis Pluvicto as the first targeted radioligand therapy for the treatment of prostate cancer just approved by FDA. Here we recommend a series of metal chelating agents that are widely applied in radioligand therapy, radionuclide drug conjugates, and radiography.
®
